However, recent studies, in particular the ADAURA study which used osimertinib, a third generation TKI, as an adjuvant for non-epidermoid NSCLC (stage IB-IIIA completely surgically resected) with an exon 19 deletion or an L858R mutation in EGFR, were positive compared to a placebo for progression-free survival [14]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.